Culture Collections

General Cell Collection Detail

ECACC General Cell Collection: NCI-H69/LX4

Supplied by: European Collection of Authenticated Cell Cultures (ECACC)
Culture Type: Cell line
Collection: ECACC General Collection
Catalogue No.: 96042329
Cell Line Name: NCI-H69/LX4
Citation Guidance: If use of this culture results in a scientific publication, it should be cited in the publication as: NCI-H69/LX4 (ECACC 96042329)
Keywords: Human Caucasian small cell lung carcinoma, drug-resistant
Cell Line Description: NCI-H69/LX4 has been established by exposure of the parent line, H69 (ECACC catalogue no. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.
Species: Human
Tissue of Origin: Lung
Growth Mode: Aggregates in suspension
DNA Profile: STR-PCR Data:

Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 11,13
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

Karyotype: Not specified
Biosafety Information: Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
Subculture Routine: Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO2; 37°C
Culture Medium: RPMI + 2mM Glutamine + 0.4µg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).
Depositor: Dr P Twentyman / Dr K Wright, MRC Clinical Oncology Unit, Cambridge, UK
Originator: Yes
Country: UK
References: Br J Cancer 1992;65:335; Br J Cancer 1986;53:529
Additional Bibliography: Not specified
Patents: None specified by Depositor
Release Conditions: No

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.

Available Formats

DNA-5ug (100ng/ul)

Back to top
Copyright © Public Health England.

Please confirm your country of origin from the list below.